Utama › Kanser Payudara › Wisconsin › Madison
Kajian klinikal Kanser Payudara di Madison, WI
22 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Madison (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Mengambil pesertaFasa 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Mengambil pesertaFasa 2
- UW Health Carbone Cancer Center, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Mengambil pesertaFasa 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Mengambil pesertaFasa 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Mengambil pesertaFasa 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Mengambil pesertaFasa 3
- University of Wisconsin-Madison ( Site 0024), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Mengambil pesertaFasa 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Mengambil peserta
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Mengambil pesertaFasa 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Mengambil pesertaFasa 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Mengambil pesertaFasa 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Mengambil pesertaFasa 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Mengambil pesertaFasa 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Mengambil pesertaFasa 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Mengambil pesertaFasa 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Mengambil pesertaFasa 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Mengambil pesertaFasa 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Mengambil pesertaKajian pemerhatian
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Mengambil pesertaFasa 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Mengambil pesertaFasa 1
- UW Carbone Cancer Center, Madison
Kajian Kanser Payudara di bandar lain
- New York City, NY134 kajian
- Houston, TX126 kajian
- Boston, MA111 kajian
- Nashville, TN80 kajian
- Los Angeles, CA72 kajian
- Edison, NJ68 kajian
- St. Louis, MO64 kajian
- Durham, NC63 kajian
- Queens, NY63 kajian
- Chicago, IL58 kajian
- Philadelphia, PA56 kajian
- Dallas, TX55 kajian
Kajian lain di Madison
- Kanser Prostat29 kajian
- Kanser Kolorektal22 kajian
- Kanser Metastatik21 kajian
- Kanser Paru-paru Bukan Sel Kecil16 kajian
- Leukemia Mieloid Akut16 kajian
- Melanoma15 kajian
- Kanser (semua jenis)14 kajian
- Kanser Ovari13 kajian
- Kanser Perut11 kajian
- Kanser Paru-paru10 kajian
- Kanser Pankreas10 kajian
- Mieloma Pelbagai9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.